201 related articles for article (PubMed ID: 24866555)
1. Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems.
Janero DR; Makriyannis A
ACS Chem Neurosci; 2014 Nov; 5(11):1097-106. PubMed ID: 24866555
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Wilhelmsen K; Khakpour S; Tran A; Sheehan K; Schumacher M; Xu F; Hellman J
J Biol Chem; 2014 May; 289(19):13079-100. PubMed ID: 24644287
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.
Di Marzo V; De Petrocellis L
Curr Med Chem; 2010; 17(14):1430-49. PubMed ID: 20166923
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.
Iannotti FA; Di Marzo V; Petrosino S
Prog Lipid Res; 2016 Apr; 62():107-28. PubMed ID: 26965148
[TBL] [Abstract][Full Text] [Related]
5. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
6. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.
Atwood BK; Wager-Miller J; Haskins C; Straiker A; Mackie K
Mol Pharmacol; 2012 Feb; 81(2):250-63. PubMed ID: 22064678
[TBL] [Abstract][Full Text] [Related]
7. TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling.
Storozhuk MV; Zholos AV
Curr Neuropharmacol; 2018 Jan; 16(2):137-150. PubMed ID: 28440188
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid Ligands Targeting TRP Channels.
Muller C; Morales P; Reggio PH
Front Mol Neurosci; 2018; 11():487. PubMed ID: 30697147
[TBL] [Abstract][Full Text] [Related]
9. The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation.
Veldhuis NA; Poole DP; Grace M; McIntyre P; Bunnett NW
Pharmacol Rev; 2015; 67(1):36-73. PubMed ID: 25361914
[TBL] [Abstract][Full Text] [Related]
10. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L; Di Marzo V
J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
[TBL] [Abstract][Full Text] [Related]
11. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
12. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
Martin BR
Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
[TBL] [Abstract][Full Text] [Related]
13. Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo V; De Petrocellis L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3216-28. PubMed ID: 23108541
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid exposure during zebra finch sensorimotor vocal learning persistently alters expression of endocannabinoid signaling elements and acute agonist responsiveness.
Soderstrom K; Poklis JL; Lichtman AH
BMC Neurosci; 2011 Jan; 12():3. PubMed ID: 21211022
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR; Stoneking SP; Ball JM; Tilghman BM; Washington CC; Hotaling KA; Johnson JO; Tobias JD
Naunyn Schmiedebergs Arch Pharmacol; 2007 Dec; 376(4):285-93. PubMed ID: 17960365
[TBL] [Abstract][Full Text] [Related]
16. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.
Pertwee RG; Howlett AC; Abood ME; Alexander SP; Di Marzo V; Elphick MR; Greasley PJ; Hansen HS; Kunos G; Mackie K; Mechoulam R; Ross RA
Pharmacol Rev; 2010 Dec; 62(4):588-631. PubMed ID: 21079038
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Vemuri VK; Janero DR; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
[TBL] [Abstract][Full Text] [Related]
18. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.
Basavarajappa BS; Hungund BL
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):287-99. PubMed ID: 12052043
[TBL] [Abstract][Full Text] [Related]
19. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids.
Oz M
Pharmacol Ther; 2006 Jul; 111(1):114-44. PubMed ID: 16584786
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
Di Marzo V; Berrendero F; Bisogno T; González S; Cavaliere P; Romero J; Cebeira M; Ramos JA; Fernández-Ruiz JJ
J Neurochem; 2000 Apr; 74(4):1627-35. PubMed ID: 10737621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
